The comparison of effects of single session corticosteroids injection in treatment of shoulder inflammatory diseases with and without ultrasonography guidance.

The comparison of therapeutic effect of ultrasound-guided and blind corticosteroid injection in shoulder impingement syndrome in patients reffering to physical medicine and rehabilitation clinic of Firoozgar hospital in year1394-1395

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017021524621N6

Enrollment

Registered

2017-04-29

Start date

2016-03-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

shoulder tendinopathy. Impingement syndrome of shoulde

Interventions

Intervention 1: Control group: Blind injection of corticosteroid in the subacromial space with lateral approach. Intervention 2: Intervention group: Ultrasound-guided injection of corticosteroid in th

Treatment - Other

Control group: Blind injection of corticosteroid in the subacromial space with lateral approach

Intervention group: Ultrasound-guided injection of corticosteroid in the subacromial space with lateral approach

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age between 20 and 80 years; Shoulder tendinopathy as positive result of specific test like Neer & Hawkins test; The willingness of patients to participate in research projects; The absence history of rotator cuff tear, diabetes, coagulation disorders, fractures, rheumatologic diseases, tumors and infections; Not having shoulder injection in last 8 weeks; The absence of intraarticular injection contraindications like anticoagulant medications consumption; The absence of corticosteroid and lidocaine injection contraindications such as allergy reaction to these medications and skin infection at the injection site; The absence of bilateral shoulder problems; VAS>4; Not pregnant or not decide to get pregnant Exclusion criteria: The willingness of patients to exit from the study at any stage of the project; Non coming patient for follow-up and evaluation during the follow-up study; Daily use of any type of pain medication by patients for the duration of study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The severity of symptoms. Timepoint: Zero, two weeks and two months after. Method of measurement: Visual Analog Scale (VAS).;The severity of symptoms and functional limitations. Timepoint: Zero, two weeks and two months after. Method of measurement: Constant score questionnaire.	—

Secondary

Measure	Time frame
Side effects. Timepoint: Two weeks and two months after. Method of measurement: Physical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKimiya Habibi Siahpoush

Iran University of Medical Sciences

Kimiya_me@yahoo.com+98 21 2676 5690

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026